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Abstract. Cisplatin (cis-Diamminedichloroplatinum II) is one of the most important chemotherapeutic agents widely 
used in treatment of many types of solid cancer. Accumulating evidence suggests that the cytotoxic activity of cisplatin 
involves both nuclear and cytoplasm component, but its biochemical and molecular mechanisms of action are still 
unclear. Its mode of action is linked to the ability of cisplatin to interact with purine bases on the DNA, causing DNA 
damage, interfering with DNA repair mechanisms and inducing apoptotic cell death in cancer cells. The major 
limitations in the clinical application of cisplatin are the numerous side effects and the development of cisplatin 
resistance by tumors. Mechanisms that can explain cisplatin resistance include the reduction in drug accumulation inside 
the cell, higher concentration of glutathione and metallothioneins, faster repair of cisplatin adducts and modulation of 
apoptotic cell death in various cells. In this article we review the pathways that cisplatin can activate in cancer cell, the 
mechanisms of resistance and clinical toxicities. A deep knowledge of mechanisms of action may lead to design of more 
efficient platinum-based antitumor drugs and provide new therapeutic strategies in cancer treatment. 
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Introduction 

 
Cancer presents the second most common cause of 
death in Serbia, right after cerebrovascular disease. 
According to National cancer database cancer mortality 
rate is higher among men than women (181 per 100,000 
men and 113.6 per 100,000 women) [1]. Lung cancer, 
colorectal cancer, and stomach cancer were among ten 
leading causes of death in men, whereas breast cancer, 
colorectal cancer, lung cancer, stomach cancer, and 
cervical cancer were among twelve leading causes of 
death in women [2]. Multidisciplinary approach to 
treatment of human malignancies includes surgery, 
chemotherapy or radiation therapy depending on the 
stage when cancer is diagnosed. Clinically useful 
chemotherapeutic drugs inhibit the processes essential for 
cancer cell growth and/or proliferation, such as blocking 
production of DNA, mRNA or proteins, directly damaging 
DNA or inhibiting components required for DNA 
replication or chromosome separation [3]. 
Cisplatin or cis-Diamminedichloroplatinum(II) is an 
effective chemotherapeutic agent that is used in nearly 
50% of all cancer patients [4]. This complex was first 
synthesized in 1845 by Peyrone, but its antitumor 
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activity was discovered by accident, thanks to the 
research of Rosenberg, the physics teacher at the 
University of Michigan in the late 1960s. The Food and 
Drug Administration approved the clinical use of this 
drug for treatment of genitourinary tumors in 1978, and 
since then it has been one of the most widely used drugs 
in cancer treatment [5]. It has been an important part of 
chemotherapeutic regimes for treatment of broad range 
of malignancies. Cisplatin success in treatment of 
testicular cancer is remarkable; its cure rate is more than 
90 percent when it is used in combination with other 
chemotherapeutics [6]. It has been used in fight against 
ovarian, head and neck, bladder, cervical, esophageal, as 
well as small lung cancer. However, many patients 
eventually relapse and become refractory to the drug. 
Drug resistance is the major complication in cancer 
chemotherapy and accounts for the failure of 
chemotherapy to cure majority of patients. The 
development of platinum analogs that display similar 
effectiveness as cisplatin, but have better toxicity profile 
and lack cross-resistance is the major task in research 
centers worldwide. 
Chemical Structure of Cisplatin 
Cisplatin is a white or yellow crystalline powder, slightly 
soluble in water and soluble in dimethylpirimidine and N, 
N-dimethylformide. It is a neutral inorganic molecule with 
molecular weight of 301,1 g/mol, density of 3,74 g/cm
3
 
and melting point at 270°C, composed of platinum ion 
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bound to two ammine groups and two chloride ions that 
are arranged in a square (Fig. 1). In metal complexes Pt 
can exist in either 2
+
 or 4
+
 oxidation state. The ammine 
groups represent carrier ligands, while chloride ions are 
leaving groups. In cisplatin the chlorides are next to 
each other. The presence of leaving groups is essential 
for biological activity of cisplatin [7]. Inside the cell, 
cisplatin loses two chloride ions and they are replaced 
by loosely bound water molecules, allowing the platinum 
to attack the DNA molecule in nucleus.  
 
Fig. 1 Chemical structure of cisplatin and transplatin. 
Figure is modified from http://chemwiki.ucdavis. 
edu/Core/Inorganic_Chemistry/Coordination_ 
Chemistry/Isomers/Geometric_Isomers%3A_ 
cis-platin 
Transplatin is an isomer that has both chloride ions 
opposite each other (Fig. 1); it causes different structural 
changes than cisplatin in cancer cells. Monoadducts, 
formed by transplatin, do not significantly change the 
structure and stability of DNA molecule [8]. 
Mechanisms of Action of Cisplatin 
Cisplatin is administered to cancer patients intravenously 
as a sterile saline solution. In the circulation, chloride 
concentration is relatively high and cisplatin remains 
neutral and can be transported throughout the body. Once 
in the bloodstream, it binds strongly to plasma proteins, 
such as albumin and transferrin, leading to inactivation of 
large amount of the applied drug [9]. Passive diffusion 
across the plasma membrane has been proposed as process 
responsible for drug transport into the cell. In the last years, 
there is growing evidence that several proteins expressed 
on the cell membrane are involved in drug uptake. Copper 
transporter, that controls intracellular copper homeostasis, 
was shown to be involved in the uptake of cisplatin [10]. 
Many cellular components, such as cytoskeletal 
microfilaments, RNA and thiol-containing peptides and 
proteins, may react with cisplatin in the cytoplasm. 
Intracellular thiol-containing molecules such as 
glutathione and metallothionein, increase inactivation of 
the drug that results in cisplatin resistance.  
Genomic DNA is the main cellular target for 
cisplatin, although only 1 percent of intracellular cisplatin 
is bound to nuclear DNA [11]. Cisplatin binds with DNA 
to form intrastrand crosslinks and adducts. DNA adducts 
formed by cisplatin inhibit DNA replication and/or 
transcription and activate several signal transduction 
pathways, culminating in the activation of apoptosis [12]. 
Cisplatin binds with DNA in two steps, first the 
bond with N7 guanine is formed, and then it binds with 
guanine or adenine in the same or opposite strand. The 
N7 atoms of guanine and adenine are the most 
accessible and cisplatin forms a broad spectrum of intra- 
and inter-strand crosslinks and all of them cause the 
distortion of the DNA. The great majority of DNA 
crosslinks are 1,2-d(GpG), and they represent 70 percent, 
while d(ApG) intrastrand adducts account for 20% of all 
lesions [13]. 1,2 intrastrand-crosslink is considered to be 
the most cytotoxic one, since inactive transplatin is not 
able to form this lesion. These lesions cause the bending 
and unwinding of the double helix and loss of function. 
Several proteins can recognize the DNA bending 
induced by specific cisplatin adducts. High mobility 
group (HMG) proteins are non-histone chromosomal 
proteins involved in gene regulation and chromatin 
structure. Protein HMG1 binds with high selectivity to 
platinum adducts in DNA [14]. In this way, bounded 
proteins act as a shield and protect DNA from repair 
mechanisms. HMBG binding modulates signaling 
pathways in the cell by diminishing the efficiency of NER, 
and it has been connected to MMR, p53 activity and 
MARK pathway [15]. Recognition of 1,2-intrastrand 
adduct by these proteins may be the first step towards the 
initiation of apoptosis. 
DNA lesions are recognized by damage recognition 
macromolecules, those can repair cisplatin DNA adducts. 
The most important families of DNA repair proteins are: 
1) nucleotide excision repair (NER) proteins, 2) mismatch 
repair (MMR) proteins and 3) DNA-dependent protein-
kinase (DNA-PK) proteins. 
Nucleotide excision repair (NER) system consists of 
at least 17 different proteins. This multiprotein complex 
recognizes intrastrand crosslinks and subsequently excises 
the DNA sequences of 27-29 base pairs oligonucleotides in 
length containing the damage [16]. The incision reaction 
on both sides of the lesion involves numerous protein 
factors such as XPA, RPA, XRC-HR23B, ERCC1-XPF 
and XPG. The enzyme DNA polymerase fills the 
remaining gap [17]. Over-expression of some genes 
involved in NER complex is associated with cisplatin 
resistance [18]. Mismatch repair (MMR) complex is ATP 
dependent multiprotein system that is crucial for normal in 
vivo response to DNA damaging drugs [19]. The MMR 
complex causes cell cycle arrest. The MMR proteins 
would try to insert the correct nucleotide on the non-
damaged strand opposite to the intrastrand adduct between 
two adjacent guanines. When it does not succeed in the 
attempt to repair the damage, the apoptotic pathway is 
activated [20]. The Ku subunit of DNA-PK protein can 
also interact with cisplatin-DNA lesions, which leads to the 
activation of DNA-PK to phosphorilate itself or other 
transcription factors. 
Oxidative stress is one of the most important 
mechanisms involved in cisplatin cytotoxicity (Fig. 2). 
Cisplatin causes oxidative stress by increasing the level 
of super oxide anions and hydroxyl radicals [21]. Under 
oxidative stress condition, excessive reactive oxygen 
species (ROS) can damage cellular proteins, lipids and 
DNA and may modulate survival signaling cascades. 
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Depending on the severity and duration of ROS exposure 
pro-survival or pro-apoptotic response pathways may be 
activated. Mitochondrial glutathione (GSH) is an essential 
molecule in the regulation of inner mitochondrial 
permeability. Cisplatin decreases intracellular concentration 
of GSH, leading in hydroxyl radical formation and 
oxidative stress, resulting in loss of mitochondrial protein 
sulfhydryl group, calcium uptake and reduction of 
mitochondrial membrane potential [22]. The molecular 
mechanisms that underlie the cytotoxic potential of 
cytoplasm cisplatin may involve the pro-apoptotic Bcl-2 
family members Bak1, the voltage-dependent anion 
channel 1 (VDAC1) and the Bak1 homolog Bax [23]. It 
is well known that mitochondrial DNA (mtDNA) is 
more susceptible than nuclear DNA to damage from 
reactive oxygen species, due to either a limited capacity 
for DNA repair or the presence of nucleosome-free 
structure [24]. Cisplatin is a potent mtDNA-targeting 
agent. Cisplatin forms crosslinks with mtDNA that is 
more vulnerable than nuclear DNA. The mtDNA adduct 
levels are higher than the nuclear DNA adduct levels, 
due to significantly higher number of guanine stretch 
sequences (target sequences of cisplatin) in mtDNA 
than in nuclear DNA [24].  
As previously noted cisplatin inter- and intra-strand 
DNA adducts can be recognized and safely removed by 
several repair systems that normally operate in the 
context of a temporary cell cycle arrest. There are two 
main checkpoints, G1/S and G2/M, in which cell cycle 
will be arrested to help the function of the repair 
machinery. The G1/S checkpoint allows DNA restoration 
before replication and G2/M facilitates the reparation of 
DNA damaged during S and G2 phases to prevent its 
segregation into daughter cells. Treatment with cisplatin 
usually induces G2 arrest through phosphorilation 
checkpoint kinases Chk1 and Chk2, activation of Cdc25C 
and its translocation to the cytoplasm which provoke cell 
arrest in G2 phase of cell cycle [25]. Meanwhile, when 
the damage is irreparable, the cell activates mechanisms 
that induce cancer cell death via apoptosis and prevent 
the passage of these cells into mitosis. Apoptosis, as a 
mode of programmed cell death, is energy-dependent 
process leading to membrane blabbing, phosphatidylserine 
externalization, cell shrinkage, chromatin condensation 
and activation of a family of cysteine proteases called 
caspases [26]. There are two major pathways of apoptotic 
cell death: the extrinsic pathway, activated by pro-
apoptotic receptor signals at the cell surface, and the 
intrinsic pathway, activated by mitochondrial signals. In 
response to DNA damage, the Bcl2 family proteins 
regulate apoptosis through cytochrome c, apoptosis 
promoting activating factor 1 (Apaf-1) and caspases 9 
and 3. 
It is known that p53 protein plays a central role in 
chemotherapy-induced apoptosis. A primary mechanism 
by which p53 induces apoptosis is through transcriptional 
activation and repression of target genes whose 
promoters contain p53-binding sites. These genes may 
activate apoptotic process via multiple pathways (Fig. 2) 
[27]. The protein p53 is “guardian of the genome” 
because it activates a host of other genes (p21/waf1, 
mdm2, GADD45 and others) that lead to cell cycle arrest 
and activation of DNA repair [28]. On the other hand, p53 
regulates cisplatin-induced apoptosis by several 
mechanisms like: activation of pro-apoptotic genes 
including PUMA [29], caspases [30], PIDD [31], 
MAPK protein family [32], as well as interaction with 
Bcl2 family proteins in mitochondria and/or cytosol 
 
Fig. 2 Molecular mechanisms of cisplatin in cancer treatments 
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[33]. The p53-negative cells also respond to cisplatin-
induced DNA damage that suggests the existence of 
alternate pathways upon the stress. 
Side Effects of Cisplatin 
Chemotherapy is associated with increased toxicity, 
especially in older patients. The efficiency of cisplatin 
administration is often limited by its side effects. 
Various studies confirmed that cisplatin induces the 
formation of ROS, responsible for the numerous side 
effects like nephrotoxicity, ototoxicity, hepatotoxicity, 
cardiotoxicity and neurotoxicity.  
The kidney is the main route for excretion of 
cisplatin and it accumulates it to a greater degree than 
other organs, which is the reason for the cisplatin-
induced nephrotoxicity. Tubular cell injury occurs in 
one third of cisplatin treated patients and manifests as 
an increase in serum urea and creatinine concentration 
and imbalanced electrolytes [34]. Proximal tubulocytes 
are the main point of cisplatin action. The concentration 
of the drug in these cells is five times higher than its 
serum concentration [35]. Pathological changes are 
most prominent in S3 segment and they are caused by 
multiple mechanisms such as oxidative stress, apoptosis, 
inflammation and fibrogenesis. Nephrotoxicity is 
cisplatin-dose-dependent [36]. Adequate hydration can 
decrease the reactive monohydrated cisplatin form and 
it is renoprotective. 
Cisplatin is the most ototoxic drug known. Between 
10 and 90 percent of treated patients develop some 
degree of hearing loss. These changes are irreversible 
and pediatric population is very vulnerable [37]. The 
destruction affects auditory sensory cells in the organ of 
Corti and both hearing and vestibular functions can be 
affected [38]. Ototoxicity is irreversible and it is 
associated with  hipoalbuminemia, application of other 
medicaments, genetic factors, renal failure, and patient’s 
age [39]. Otoprotective therapy should be administrated. 
Intratympanic application of the drug is the most 
effective, without compromising antitumor effect.  
High dose of cisplatin may cause hepatotoxicity. 
Oxidative stress appears to play an important role in 
cisplatin-induced hepatotoxicity liver injury [40]. Cisplatin 
therapy has been associated with mild elevation of 
transaminases and bilirubin in circulation [41]. Recent 
studies show that administration of high doses of selenium 
and vitamin E has protective effect on liver injury [42]  
Antineoplastic therapy with cisplatin induces lipid 
peroxidation of cardiac membranes leading to serum 
elevation of lactate dehydrogenase and creatine kinase. 
Arrhythmias and prolongation of QT-interval have been 
reported in vulnerable individuals [43]. 
Cisplatin is thought to act on the dorsal root ganglion to 
generate both transient and chronic neuropathies, which 
explain the primary sensory neuropathy commonly 
observed in patients treated with cisplatin [44]. Anti-
oxidant compounds are being developed to prevent these 
toxic side effects.  
Cisplatin administration results in side effects 
common to most cytotoxic agents such as nausea, 
vomiting, myellosuppression, gastrotoxicity and some 
reproductive toxic effects [45]. 
Development of Cisplatin-induced Resistance 
Tumor cell resistance to chemotherapeutic drugs is a 
barrier to improving outcomes in these patients. 
Cisplatin resistance is a multifactorial phenomenon and 
may include changes in cellular uptake, decreased influx 
or increased efflux of drug, glutathione or metallothionein 
conjugation or drug detoxification. The increased DNA 
repair and inhibition of apoptosis is the significant 
mechanism of resistance. The resistance can be intrinsic, in 
which the drug is ineffective from the onset or acquired 
resistance, in which a drug is initially beneficial but 
becomes ineffective over time [46].  
Reduced drug accumulation is predominantly caused 
by defect in the uptake of a drug. It has been further 
confirmed in human ovarian carcinoma cell line that 
cisplatin, at plasma concentration, rapidly downregulates 
protein expression of Ctr1 [47]. Two other copper 
transporters have also been implicated in resistance to 
cisplatin: ATP7A and ATP7B. These copper transporters 
are responsible for the export of copper from the cell. High 
levels of ATP7A and ATP7B expression lead to cisplatin 
resistance [48].  
In the cytoplasm aquated cisplatin reacts with thiol 
containing compounds including glutathione and 
metallothioneins. Glutathione-S-transferase catalyses 
the reaction where cisplatin is conjugated with glutathione 
and therefore, cisplatin can not bind with DNA and other 
cellular targets. In some malignant tissues, there is a 
positive correlation between resistance to treatment and 
cellular level of glutathione as well as over expression of 
GST and other enzymes involved in glutathione 
metabolism [49, 50]. Metallothioneins, a family of low 
molecular weight thiol-rich proteins, can bind cisplatin in 
cytoplasm leading to drug inactivation in some tumor cell 
lines [51, 52, 53].  
Alterations of the DNA repair pathways are important 
for mediating resistance. Studies of testicular and ovarian 
carcinoma cell lines showed a deficiency in NER 
mechanism in cells that were sensitive to platinum therapy 
[54, 55]. The NER is the main repair pathway that involves 
recognition of the damage and incision that requires 
various proteins including ERCC-XPF. The level of 
ERCC1 protein inversely correlates with the response to 
chemotherapy in gastrointestinal and non-small cell lung 
carcinoma [56, 57]. 
Resistance mechanisms, therefore, arise as a 
consequence of intracellular changes that either prevent 
cisplatin from interacting with DNA, interfere with DNA 
damage signals for activating the apoptotic machinery, 
or both. More than one mechanism is usually observed 
in resistant cells, and this contributes to the multifactorial 
nature of cisplatin resistance. To minimize cisplatin 
resistance, combinatorial therapies were developed and 
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have been proven to be more effective in defeating cancer. 
The main goal is to find compounds that are less toxic, 
have no cross-resistance and possibly are more efficient 
than cisplatin. Drug resistance is the single most common 
reason for discontinuation of the drug.  
Development of New Platinum-based 
Antitumor Drugs 
Different modifications of cisplatin have been investigated 
in order to obtain a drug that has better toxicity profile and 
wider therapeutic spectrum than cisplatin. In order to 
reduce toxic side effects and overcome cancer cell 
resistance, new platinum drugs have been developed. 
Although a large number of platinum compounds 
underwent in vitro testing, less than a thirty entered clinical 
trials [58].  
Cisplatin, carboplatin and oxaliplatin (Fig. 3) are 
worldwide approved drugs that have a major role in human 
oncology.  
The second generation platinum drug carboplatin was 
introduced into cancer therapy in 1989, for treatments of 
ovarian cancer. The replacement of the chloride groups of 
cisplatin by cyclobutanedicarboxylate ligand of carboplatin 
(Fig. 3) provides good aqueous solubility and greater 
stability and leads to diminishing side effects. Carboplatin 
can be applied in higher doses with possibly better effects. 
The downside is that carboplatin and cisplatin are cross 
resistant.   
Newly acquired knowledge about mechanism of 
tumor resistance to platinum drugs enabled discovery of 
third generation drugs such as oxaliplatin that is effective 
in colon cancers, which were thought to be resistant to 
platinum compounds. Oxaliplatin has a different carrier 
ligand diaminocyclohexane (DACH) [59], that has  less 
cross-resistance and a more favorable toxicity profile. 
Satraplatin, lipophilic platinum (IV) complex is the 
first platinum compound active after oral administration 
and is currently in different phases of clinical research 
[60]. Platinum (IV) complexes are less reactive in 
ligand substitution reactions compared to their platinum 
(II) analogues, and they have reduced toxicity and a 
smaller fraction of the drug deactivated on its pathway 
to target cell [61]. The platinum (IV) complexes are in 
focus and they have been tested in various cancer cell 
lines [62, 63]. Newly synthesized platinum (IV) complexes 
are tested for cytotoxic activity against various cell lines 
and some of them showed similar activity as cisplatin 
towards human ovarian carcinoma, breast cancer and 
colon carcinoma cell lines [64, 65]. 
Picoplatin is platinum coordination complex which, 
during in vitro testing, showed activity against several 
cisplatin-resistant and oxaliplatin-resistant cell lines. 
Unfortunately, it failed to produce significant clinical 
results compared to standard therapy for lung cancer [66]. 
Multinuclear complexes are another class of platinum 
complexes that showed activity in both cisplatin resistant 
and cisplatin sensitive cell lines. They are di-, three-, or 
tetra-nuclear compounds, in which platinum centers are 
connected by rigid or flexible bridges [67, 68]. The DNA 
binding of these compounds is structurally different from 
binding of cisplatin and its analogues and they exhibited 
cytotoxicity in cancer cell models, and some of them 
entered clinical trails [69].  
Platinum drugs resistance can also be circumvented by 
improved delivery of the drug to tumor tissue. This can be 
achieved by linking platinum-based drug to a water 
soluble, biocompatible co-polymer [70]. In some cases, 
such as an ovarian cancer, local application of a drug, 
through intraperitoneal injection might be adequate [71]. 
Conclusions 
Cisplatin plays a major role in the treatment of a variety 
of malignances. Cisplatin and other platinum-based 
compounds are cytotoxic drugs which kill cancer cells 
by damaging nuclear and mitochondrial DNA, inhibiting 
DNA replication and mitosis and inducing apoptotic cell 
death. Cisplatin-induced damages are considered to be an 
important trigger of p53 activation that leads to cell 
apoptosis. On the other hand, cisplatin can also react 
with other cellular components such as membrane 
phospholipids and proteins, cytoskeletal microfilaments, 
thiol-containing biomolecules and cytoplasm proteins, 
resulting in cell death depending upon the mechanism  
of DNA damage. Unfortunately, the therapeutic effects 
of cisplatin are often limited due to cell resistance which 
develops through changes in drug transport, detoxification, 
DNA repair and apoptosis signaling pathways. Dose 
dependent toxicity and acquired and intrinsic resistance are 
still the major obstacles in platinum based therapy. 
Therefore, the comprehensive understanding of the 
mechanisms of action and tumor resistance might be useful 
in defining new strategies in the search for the new 
therapeutics with improved pharmacological properties. 
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